Alpine Immune Sciences to Present at Upcoming Investor Conferences

May 24, 2019

SEATTLE--(BUSINESS WIRE)--May 24, 2019-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in three upcoming investor conferences in June.

Jefferies 2019 Healthcare Conference

Date: Thursday, June 6, 2019

Time: 2:00 p.m. Eastern Time

Location: New York, NY

Raymond James Life Sciences and MedTech Conference

Date: Wednesday, June 19, 2019

Time: 1:15 p.m. Eastern Time

Location: New York, NY

JMP Securities Life Sciences Conference

Date: Thursday, June 20, 2019

Time: 1:30 p.m. Eastern Time

Location: New York, NY

A live webcast of each presentation will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events. A replay of the presentations will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of functional immune therapeutics. Alpine is employing directed evolution to create potentially powerful multifunctional immunotherapies to improve patients’ lives. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28 antagonist, engineered to reduce pathogenic immune responses. ALPN-101 is currently enrolling a Phase I healthy volunteer trial. The second, ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 costimulator intended to combine checkpoint inhibition with T cell costimulation - an approach currently absent from approved checkpoint therapies. Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.

Source: Alpine Immune Sciences, Inc.

Investor Relations:
Pure Communications
Courtney Dugan, 212-257-6723
[email protected]

Media Relations:
Pure Communications
Jennifer Paganelli, 347-658-8290
[email protected]